Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD - Wikidata - awgldk - TriplyDB

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

http://www.wikidata.org/entity/Q34608306

about

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration The clinical utility of aflibercept for diabetic macular edema The role of aflibercept in the management of diabetic macular edema Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.A Review of Ranibizumab for the Treatment of Diabetic Retinopathy.Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration.Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Current intravitreal pharmacologic therapies for diabetic macular edema.Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders.Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration.Alterations in Circulating Immune Cells in Neovascular Age-Related Macular Degeneration.Molecular pathogenesis of retinal and choroidal vascular diseases.Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials.Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration: Complement activation in AMD.Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration.Efficacy of Antibody Delivery to the Retina and Optic Nerve by Topical Administration VEGF regulates local inhibitory complement proteins in the eye and kidney.Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs.Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy The remote effects of intravitreal anti-VEGF therapy.Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?Effect of intravitreal ranibizumab on the ocular circulation of the untreated fellow eye.Fellow eye effect of unilateral intravitreal anti-VEGF injections in eyes with diabetic macular edema.Ten years of anti-vascular endothelial growth factor therapy.One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion.Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity.Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study.Clinical pharmacology of intravitreal anti-VEGF drugs.

P2860

Q24193614-3B4543B3-F89D-4417-9D36-61C6C85AA384 Q26771522-59667D5D-256A-418C-8C74-AC5EB03D33D5 Q26783575-62B25708-6119-4391-B56A-7CDCC8A52DE0 Q26798348-D813FFC2-03AC-4A8E-A3D1-E59D9EFE3628 Q27007119-DB068D44-5AD7-4327-A40D-B91BD61D00F9 Q28066675-4E9393FF-268C-45BA-AAA2-06864277B9D1 Q28081000-066832AD-A94A-46FE-B13F-9DAC27000C73 Q28550616-B30F7E3F-36D9-45DE-9C88-805F7742F23F Q30244247-AB18E25E-7165-44CE-A585-24073828FE9F Q30490738-BA07FD26-EF4B-43C5-B1E1-C5D5E3698CD9 Q33740152-3327E60F-97C2-41B2-8456-970032E17F4B Q33790460-9957EFD6-C720-4FBF-90E2-DD73D1C721C4 Q35016867-48279E2C-58F0-4DEA-8A66-17C595CDCC98 Q35650268-88ACD754-83AA-4125-BD1D-B3FC0342AE1A Q35884984-9F9121EB-BA9A-4110-AB1F-9F5CECD7E67C Q36013973-0E469A69-5B80-4F19-B0F1-7BE123BDD0A9 Q36039050-E5F84385-9BC1-4D61-989F-75A18C2E315C Q36200924-75177B34-1EA5-4229-8C49-E862F93E00AC Q36209048-2E97CFBD-84D4-4378-AEB3-3BC0FDE477FB Q36287622-5D665E22-A928-4B87-B251-80D700A43C8B Q36296789-A1ACAFA3-087C-4320-BDF1-F2895DDBD94A Q36338786-A00E9141-1FE7-4C68-90F1-F89582F146B6 Q36583714-A5C1DCDC-B941-4A6B-AE3D-3C5E097A3BEB Q36757415-2201625F-DAC4-401C-AAAF-073B8756517F Q36881990-EA837609-2A08-4E6B-ABDD-C7507D7EB5C4 Q37545004-828D064C-9AE1-4369-936D-4851990B0CDB Q38528148-DAA6E137-6384-46E9-BB4E-2C654C982A75 Q38897856-0331FDD2-C5A5-438B-9274-AD35C474EF07 Q40358167-293CAF5A-3272-4873-AB9E-22DFE3FC5301 Q40426766-2DD34EC9-68DA-4450-905B-1AE75C399D9F Q40990867-962EC9FA-FFB5-4E25-B4C6-605D359A6EDE Q41222963-FE2B684F-7BD7-4DD0-964A-2B4206FD56CD Q43149049-2E28308C-B7F6-431A-A9A2-AD35D3EBF761 Q46407140-99C5696C-08D7-48EE-8C60-69ADD74CAAF8 Q47162242-7912AFF4-CB62-46AA-962F-2256B84C0812 Q47198245-6180E4D1-D35D-4020-BDE8-5B04EA15B8F9 Q47229423-3C72B4F7-A441-4C8E-9B71-27429502AE3F Q47405816-3C461739-3B33-46AD-A6E8-B09632DE525D Q47761710-960EA6EA-33A6-47C8-A933-D6580E00FD8A Q48109878-E2CA09A3-ED83-422B-9A10-5BA28E387714

P2860

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

http://www.wikidata.org/entity/Q34608306

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@ast

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@en

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@nl

type

label

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@ast

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@en

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@nl

prefLabel

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@ast

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@en

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@nl

P1433

Q34608306-09D4AD59-7E0E-4800-BFB8-77EE85C10A21

P1476

Q34608306-D4B1861A-1BE7-4014-BBF1-6A028D5182A2

P2093

Q34608306-11DB9EB7-E318-4771-83CD-1E9DDED76EE0

Q34608306-3667D180-2624-446C-A4B8-5FD1F6C1FD0C

Q34608306-3BCA9DF4-9488-42D4-9068-DFB618119212

Q34608306-3D8B83FA-4D09-432C-A617-3C5C917881A4

Q34608306-73B4756E-60FD-4AB9-B3C8-75EC591747DA

Q34608306-9F3892FA-E2F5-4F06-82F7-8053D2A019C1

Q34608306-A5ACE74E-18DF-43B4-894E-06AFED16235E

Q34608306-C79602E4-06D2-4FAC-8F0C-42B05A1D0058

Q34608306-CD33A768-F655-4B27-9BAE-8EAF01630510

Q34608306-D756030C-84F5-4CC8-B4DA-C64FB4213F93

P2860

Q34608306-170A5B58-214B-46F1-95C9-8F06636D6E08

Q34608306-19B5F615-AA98-4464-A22D-EF67CA9309A6

Q34608306-1DC10F27-FBEE-495F-A00F-F4938ACA270F

Q34608306-2422C159-6D72-45B2-BC17-C853A90232DE

Q34608306-26046AF1-3C99-445B-A8A8-8B89313C4F06

Q34608306-26CAF922-2554-4A5A-9658-71D194882C56

Q34608306-381DA96C-4AD7-4BD3-A5FD-C84B9F60A56E

Q34608306-42891AE7-1AE0-43B3-9253-3D734BB2305A

Q34608306-4450A58B-018B-4E71-95FF-7C9ED1978AE2

Q34608306-4A00DB94-6488-4216-B86F-DC068F07B27C

P304

Q34608306-3255DB94-A7E3-4F7D-8B12-5D6B2BD73C01

P31

Q34608306-F8D7C00F-6BE7-49A9-8CB7-F569A0581520

P356

Q34608306-29C3F26F-E376-4427-A0AB-CE15946DB181

P407

Q34608306-7D949C4D-DFDB-4F8D-99C1-E491333D7D7A

P433

Q34608306-CD2660D8-9BF9-47A0-964E-3875FF51BBB3

P478

Q34608306-45F2F64B-6857-4637-80E0-05E07106FD99

P50

Q34608306-91F1DC00-5EE0-4D06-B4E3-227FD7236A5D

P577

Q34608306-C9F4CFD0-BDF2-4031-9FEE-B06AD6E3BC5D

P5875

Q34608306-28DB493C-6861-4279-8F6B-6583B681F01E

P698

Q34608306-4CECB80A-BDA2-4589-94F5-2FA9611E6834

P921

Q34608306-41162F1B-F010-4A0A-B0F0-B4AB31CC632E

P932

Q34608306-35574B03-9014-45AB-A099-1749EDEB8E2B

P356

BJOPHTHALMOL-2014-305252

P1433

British Journal of Ophthalmology

P1476

Systemic pharmacokinetics foll ...... patients with neovascular AMD

@en

P2093

Alessandro A Castellarin

http://www.w3.org/2001/XMLSchema#string

Dante Joseph Pieramici

http://www.w3.org/2001/XMLSchema#string

Dilsher S Dhoot

http://www.w3.org/2001/XMLSchema#string

Jennifer E Visich

http://www.w3.org/2001/XMLSchema#string

Kha Le

http://www.w3.org/2001/XMLSchema#string

Ma'an A Nasir

http://www.w3.org/2001/XMLSchema#string

Melvin D Rabena

http://www.w3.org/2001/XMLSchema#string

Nathan C Steinle

http://www.w3.org/2001/XMLSchema#string

Robert L Avery

http://www.w3.org/2001/XMLSchema#string

Robert See

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines

FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.

Adverse effects of anticancer agents that target the VEGF pathway.

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.

Anti-macular degeneration agents.

P304

1636-1641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BJOPHTHALMOL-2014-305252

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263740200

http://www.w3.org/2001/XMLSchema#string

P698

25001321

http://www.w3.org/2001/XMLSchema#string

P921

P932

4251300

http://www.w3.org/2001/XMLSchema#string